WO2025235850A1 - Improved polychromatic phototherapy device and method - Google Patents

Abstract

A polychromatic phototherapy device for blood treatment including a cuvette assembly in a casing transporting blood through a hollow quartz cuvette removably installed in the casing, the cuvette has a plurality of clear quartz tubes connected to one other to form a single flow path through the cuvette. A first cuvette tube located at the bottom of the cuvette, a second cuvette tube located above the first tube, and a third clear cuvette tube located above the second quartz tube. A plurality of light sources located adjacent the cuvette including a source of UVA light, a source of UVC light, and a plurality of LED light sources configured to focus concentrated light beams on the blood as the blood is conveyed through the hollow continuous tube of the cuvette.

Description

IMPROVED POLYCHROMATIC PHOTOTHERAPY DEVICE AND METHOD

CROSS-REFERENCE TO RELATED APPLICATION(S)

[0001] This application claims priority to provisional application 63/644,709 filed May 9, 2024 to the extent allowed by law.

TECHNICAL FIELD

[0002] This disclosure relates to an improved polychromatic phototherapy device and method and, more particularly, to a photoluminescence blood treatment unit and method.

BACKGROUND

[0003] Many illnesses develop from the body’s inability to buffer free radicals through inadequate intracellular proteins. The application of oxidative and light therapy in measured doses restores the body’s ability to buffer free radicals, activate immune function, and correct cellular metabolism. Once blood, treated with light therapy, is reintroduced into the body, that treated blood delivers small doses of light energy into the body and the immune system receives a blueprint of destroyed pathogens which it analyzes and subsequently produces antibodies for. Ultraviolet light exposure to the blood and its components can result in damage to the DNA of pathogens, killing them and/or rendering them unable to replicate, thereby resulting in an autogenous “vaccine”-like effect in the blood. The ultraviolet blood irradiation promotes the coagulation of bacteria by creation of an autogenous vaccine, increases the germicidal properties of blood, and increases the number of antibodies in the body.

[0004] U.S. Patent No. 12,083,260, issued September 10, 2024, titled "Polychromatic Phototherapy Device and Method," in which the present applicant is the sole named inventor, discloses a polychromatic phototherapy device for blood treatment as the blood passes through a triple quartz tube cuvette assembly. Light sources focused on the cuvette include a dual wavelength UVA light source, a UVC light source, a dual wavelength red LED light source, and amber, green and blue LED light sources. The device of this patent does not include a violet LED light source nor an infrared LED light source focused on the cuvette. Further, the device of this patent does not include the ability to selectively pulse the LED light sources as the LED light sources are focused on the cuvette.

SUMMARY

[0005] This disclosure relates generally to a polychromatic phototherapy device and method. Multiple sources of UV and LED light are applied to blood passing through a triple-pass cuvette located adjacent to the light sources. The high energy light sources emit dual wavelengths in the UVA range, and a high output wavelength in the UVC range. Further photonic energy is generated from 60 watts of highly focused dual wavelength red LED lights, low-level green LED lights, violet LED lights and infrared LED lights emitted from LED strips of light sources in the visible spectrum, except for the infrared light sources. Each light source has been shown to have specific biological benefits. Each LED light source is enclosed in an individual focusing lens assembly. The LED light sources are operable to apply pulsed LED light to the blood to disable pathogens

[0006] These and other aspects of the present disclosure are disclosed in the following detailed description of the embodiments, the appended claims and the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] The various features, advantages, and other uses of the apparatus will become more apparent by referring to the following detailed description and drawings, wherein like reference numerals refer to like parts throughout the several views. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity.

[0008] FIG. 1 is a general diagram of the light spectrum wavelengths;

[0009] FIG. 2A is a diagram of normal DNA, prior to ultraviolet light exposure;

[0010] FIG. 2B is a diagram of abnormal DNA, after ultraviolet light exposure;

[0011] FIG. 2C is a diagram of thymine DNA produced by ultraviolet light exposure;

[0012] FIG. 3 is a chart of natural sunlight regarding relative intensity as to wavelength;

[0013] FIG. 4 is a chart of ultraviolet doses required for inactivation of microbiological pathogens, such as those found in blood;

[0014] FIG. 5 is a chart of ultraviolet doses required for inactivation of viral bodies; [0015] FIG. 6 is a chart showing photo dynamic therapy;

[0016] FIG. 7 is a diagram showing the radial artery and the ulnar artery of a human hand;

[0017] FIG. 8 is a schematic diagram showing ozone or oxygen therapy;

[0018] FIG. 9A is a front perspective view of the housing for the first embodiment of the polychromatic phototherapy device in accordance with implementations of this disclosure;

[0019] FIG. 9B is a front view of the electronic touch screen display panel of the housing of FIG. 9A, showing switches for activating the UV and LED light sources inside the housing;

[0020] FIG. 9C is a front view of the electronic display of the housing of FIG. 9A, showing switches for initiating the pulse feature of the LED light sources inside the housing;

[0021] FIG. 9D is a front view of the electronic display panel of the housing of FIG. 9A, showing touch buttons and displays for setting pulse rates for the LED light sources inside the housing;

[0022] FIG. 10 is a partial perspective schematic view of the front and rear light assemblies located inside the housing of FIG. 9A;

[0023] FIG. 11 is a cross section schematic view of the front and rear light assemblies taken along line A-A of FIG. 10;

[0024] FIG. 12 is an elevation view of the front light assembly;

[0025] FIG. 13 is a front elevation view of the rear light assembly;

[0026] FIG. 13A is a detail cross-section view of the lens structure of each of the LED light strip assemblies of FIGS. 12 and 13;

[0027] FIG. 13B is a detail and partial assembly view of a bracket used to secure the U- shaped end of the UVA and UVC light tubes to their respective light assemblies;

[0028] FIG. 14 is a front perspective detail view of the triple quartz tube cuvette assembly of the first embodiment of the polychromatic phototherapy device;

[0029] FIG. 15 is a detail perspective view of the reflective tray that removably supports the triple quartz tube cuvette assembly of Fig. 14;

[0030] FIG. 16 is a front perspective view of an embodiment of the polychromatic phototherapy device, showing a pair of wrist pad accessories electrically connected to the housing of FIG. 9A in accordance with implementations of this disclosure;

[0031] FIG. 17 is a front view of one of the wrist pads shown in FIG. 16; [0032] FIG. 18 is a flow diagram of a process for treating blood with the polychromatic phototherapy device using a push-pull syringe technique in accordance with implementations of this disclosure;

[0033] FIG. 19 is a flow diagram of a process for treating blood with the polychromatic phototherapy device using a saline bag infusion technique in accordance with implementations of this disclosure;

[0034] FIG. 20 is a flow diagram of a process for treating blood with the polychromatic phototherapy device using an in-line multipass Zotsmann or Hermann hyperbaric ozone technique in accordance with implementations of this disclosure;

[0035] FIG. 21 is a flow diagram of a process for treating blood with the polychromatic phototherapy device using a first embodiment of a veterinary syringe technique in accordance with implementations of this disclosure.

DETAILED DESCRIPTION

[0036] Many illnesses develop from the body’s inability to buffer free radicals through inadequate intracellular proteins. The application of oxidative and light therapy in measured doses restores the body’s ability to buffer free radicals, activate immune function, and correct cellular metabolism. Once blood, treated with light therapy, is reintroduced into the body, that treated blood delivers small doses of light energy into the body and the immune system receives a blueprint of destroyed pathogens which it analyzes and subsequently produces antibodies for. Ultraviolet light exposure to the blood and its components can result in damage to the DNA of pathogens, killing them and/or rendering them unable to replicate, thereby resulting in an autogenous “vaccine”-like effect in the blood. The autogenous vaccine-like effect is produced when the primary blood treated by ultraviolet light is reintroduced back into the body, the primary blood carries the photonic light energy to the untreated portion of the blood in the body, inducing secondary radiation that is subsequently emitted. The ultraviolet blood irradiation promotes the coagulation of bacteria by creation of an autogenous vaccine, increases the germicidal properties of blood, and increases the number of antibodies in the body.

[0037] Phototherapy comprises oxidation and irradiation of the blood providing improved microcirculation and oxygenation of tissues, anti-inflammatory effects, stimulation of the immune system, increased tolerance of the body towards radiation and/or chemotherapy, cardiovascular protection through increased metabolism of cholesterol, uric acid, and glucose, resolution of vascular spasms, and powerful anti-infection properties. Mitochondria are thought to be a likely site for the initial effects of light, leading to increased adenosine triphosphate (ATP) production, modulation of reactive oxygen species, and induction of transcription factors. These effects, in turn, lead to increased cell proliferation and migration, particularly by fibroblasts, modulation in levels of cytokines, growth factors and inflammatory mediators, and increased tissue oxygenation.

[0038] Ultraviolet (UV) radiation is part of the electromagnetic spectrum, shown in FIG. 1, with a wavelength range of 100 - 400nm, that is shorter than that of visible light, which has a wavelength range of 400 - 700nm, but is longer than that of x-rays, which have a wavelength range less than lOOnm. UV radiation is divided into four distinct spectral areas, which include vacuum UV (100 - 200nm), UVC (200 - 280nm), UVB (280 - 315nm), and UVA (315 - 400 nm). UV light in its multiple wavelengths comprises approximately 10% of sunlight, as shown in FIG. 3.

[0039] Ultraviolet (UV) light is very effective in disabling bacteria and viruses by damaging their DNA. Normal DNA is shown in FIG. 2A while DNA damaged by UV light is shown in FIG. 2B. The UV light causes numerous cytosine and thymine bases to form covalent bonds with themselves and each other, producing dimers, mainly thymine-thymine dimers as shown in FIG. 2C, which makes it difficult for enzymes to make proper copies of DNA. The enzymes will either completely skip such areas without adding a complementary base or add one at random that may well be the wrong one, which produces serious metabolic problems thereby killing the pathogen.

[0040] When microorganisms are subjected to UV light, cellular DNA absorbs the energy by purines and pyrimidine bases, causing adjacent thymine molecules to link together. Linked thymine molecules are unable to encode adenine on messenger RNA molecules during the process of protein synthesis. Moreover, replication of the chromosome in binary fission is impaired. The damaged organism can no longer produce critical proteins or reproduce, causing the organism to quickly die. UV light is especially effective in killing viruses. However, UV light kills far fewer bacteria than one might expect because of the bacteria’s DNA repair mechanisms. Once DNA is repaired, new molecules of RNA and protein can be synthesized to replace the damaged molecules. Viral bodies generally require more energy to deactivate or kill than pathogens, as shown in FIGS. 4 and 5.

[0041] A polychromatic phototherapy device of the present disclosure comprises multiple elements which are designed to work synergistically in the treatment of auto-immune, viral, bacterial, fungal, and terminal diseases with a minimally invasive photoluminescence blood treatment unit specifically designed to safely expose a small portion of a patient’s blood through precisely controlled exposure to a full spectrum of light, including wavelengths known to increase immune response. The polychromatic phototherapy device is designed to deliver a significant amount of wide spectrum photonic energy over a prolonged period of time via an energetic photonic infusion of the blood.

[0042] The polychromatic phototherapy device utilizes multiple light sources, including enhanced spectrum, high energy light sources emitting wavelengths from 253.7 OOnm (UVC light) to 825nm which is well beyond the visible light range. The polychromatic phototherapy device is equipped with both a high power dual wavelength UVA light source and a high output UVC light source. Further photonic energy is generated from 60 watts of highly focused, high power LEDs, whose emitted energy is in the visible spectrum. The combined UV sources deactivate the DNA of bacteria, viruses, and other pathogens, thereby destroying their ability to multiply and cause disease. The polychromatic phototherapy device enables the medical community to treat chronic conditions, as well as acute conditions, including Dengue, Zika, HIV, Coronavirus 19, septicemia, and snake and spider bites.

[0043] Additionally, the principle behind the triple UV light emission architecture of the polychromatic phototherapy device of the present disclosure is based in the Krebs Cycle and is designed to propel and promote energetic ability to increase the mitochondrial electron transfer. The device 10 (FIG. 9A) accomplishes this by providing peak energy absorption spectrums unique to both NAD+ and NADH. Nicotinamide adenine dinucleotide is involved in redox reactions, carrying electrons from one reaction to another. The coenzyme is, therefore, found in two forms in cells. NAD+ is an oxidizing agent that accepts electrons from other molecules and becomes reduced. This reaction forms NADH, which can then be used as a reducing agent to donate electrons. These electron transfer reactions are the main function of NAD. However, NAD is also used in other cellular processes, the most notable one being a substrate of enzymes that add or remove chemical groups from proteins in posttranslational modifications. [0044] Blood treated with the improved polychromatic phototherapy device facilitates the following: renders virus and bacteria unable to replicate; increases the capabilities for oxygenation by activating the 2, 3, DPG enzyme system, which potentiates oxygen from the heme complex into the tissues; enhances mitochondrial energy deficiencies; stimulates lymphatic detoxification by restoration of functional chylomicron Brownian movement within the blood; activates immune cells, such as NK cells, neutrophils, and macrophages, and assists in the balancing of cytokine production, which activation aids in the destruction of various microorganisms, fungi, viruses, and bacteria; activates NAD+; dismantles nagalese, which is a protein produced principally by cancer, viruses, and some bacterium and disables the glycoprotein which is the basis for the body producing GCMAF, which is also a glycoprotein which binds to the macrophage and acts as a switch to turn on the macrophage function; activates many other cytotoxic immune cells such as NK cells; influences Zeta potential, which refers to the free flowing components of red blood cells (RBC); and photo activates curcumin, which sometimes is used to improve immune function and attack cancers..

[0045] Referring to FIGS. 9A-13B, a first improved embodiment of a polychromatic phototherapy device 10 of the present disclosure is shown. The polychromatic phototherapy device 10 utilizes eight primary wavelengths in the process of deactivating pathogens while up regulating immune response, increasing nitric oxide (NO), balancing redox, improving blood flow, and enabling simultaneous photodynamic therapy, as shown diagrammatically in FIG. 6. The presently disclosed improved device also uses the eight primary wavelengths of light to deactivate blood borne pathogens. These light sources also have the capacity to simultaneously, or solely, photoactivate photo-sensitive substances that subsequently absorb electrons and act as electron donors in the process of photoinactivation of pathogens.

[0046] Referring to Fig. 9 A, the polychromatic phototherapy device 10 comprises a touch display screen 9 with six independently controlled light source switches 12. The device 10 also includes sliding intensity control switches 14, and USB ports 16. Switches 14 are used to change the intensity of one of more accessory light sources when connected into USB ports 16. The six independently controlled light sources in this illustrated embodiment, as described in detail below, include a dual wavelength UVA light source, a high output UVC light source, two double wavelength red LED light assembly strips, one violet LED light assembly strip, one green LED light assembly strip, and two infrared light assembly strips. Switches 12 are independent controls to turn on and turn off the individual light sources, providing the operator with full control of the blood treatment.

[0047] Touch screen 9 also includes a manually operable switch 15 (FIGS. 9B, C) that is used to vary the pulse rate of the LED light sources. The pulse rate can be varied in a range from 0.1 cycles per second to 99,999 cycles per second, in 0.1 cycle increments. The pulse rate can be varied for any combination of the LED lights. The pulse rate of the UVA and UVC light sources cannot be changed. In the illustrated embodiment, pulse generation is from a Raspberry Model 3B+ or Model 4. Other suitable pulse generators as are known in the art may also be used. It has been noted that pathogens respond to pulse rates. There is a phenomenon known as M.O.R., or Mortal Oscillatory Rate, which is the pulse rate that destroys or disables pathogens. Pulse rates can stimulate biological processes and promote healing from an injury, such as a shoulder or knee injury, for example. Wrist pads (Fig. 17) can also be used to resolve back injury.

[0048] Pulsed light therapy in the treatment of blood provides several advantages. Pulsed light allows higher peak power while maintaining a lower average power, which can help penetrate deeper into tissues and blood vessels. This is important for reaching pathogens within the bloodstream. Pulsed light delivers energy to the bloodstream in short bursts, reducing heat accumulation in the blood and making the treatment safer for long exposure times. Pulsed frequencies can enhance cellular responses, such as reasonable effects where certain pathogens absorb energy at specific frequencies, potentially disrupting the pathogens. This is similar to how resonant frequencies destroy microorganisms through mechanical oscillation.

[0049] Many pathogens in the blood, including bacteria and viruses, may be more sensitive to pulsed energy at specific frequencies, as the pulsed energy interferes with the metabolism and replication cycles. Studies also suggest that pulsed light can cause oxidation stress in pathogens, making them more vulnerable. Pulsed light can also stimulate mitochondrial function and adenosine triphosphate (ATP) production, boosting immune system function and aiding in detoxification. This may help the body clear pathogens more efficiently than continuous frequency exposure. Pulse light may also disrupt the ability of pathogens to adapt over time, making the treatment more effective over time.

[0050] Referring to FIG. 9B, the operator can activate any and/or all of the LED light sources by touching the desired number of manually operable light switches 12. When depressed, a selected light switch or switches 12 will become illuminated from beneath, showing that the designated light source is activated. Also, FIG. 9B illustrates the manually operable "All Off' switch 17. If for any reason, the light sources need to be turned off, such as for example to clear a clot at the venipuncture site, the "All Off switch 17 is depressed, deactivating all of the light sources. Fig. 9C shows a "Restart Prev" button 19 that, when depressed after all of the light sources have been deactivated, will reactivate the system with the same settings as previously selected.

[0051] Referring to FIG. 9D, when the "Setup Pulse" button 15 (Figs. 9, B, C) is activated, the screen 21 appears on touch screen 9. To set a pulse rate for an LED light source, the selected pulse rate is entered using buttons 23, and the selected pulsing frequency will appear in block 25. Next, "OK" button 27 is activated after the pulse rate for the selected LED light strip or strips is entered.

[0052] The polychromatic phototherapy device 10 can also include and selectively activate two high optical density double wavelength photo red/I.R. wrist pads 18, as shown in FIGS. 16 and 17, connected to the device 10 through the USB ports 16 that provide optional photodynamic therapy treatment via the radial artery and the ulnar artery (FIG. 7), which arteries have significant blood flow and are relatively shallow and easy to access, when used with photo-active substances described above.

[0053] The intensity of the wrist pads 18 (Fig. 17) are controlled by the four sliding intensity control switches 14, located on display panel 9, which allow the user to increase and/or decrease the intensity of the deep red/photored LED lights emitted by the wrist pads 18. Deep red/ photored LED lights are densely populated when applied to the wrist area to promote the photodynamic therapy treatment, increase circulation, and activate liposomal methylene blue, with added deoxycholic acid and minerals, if used, when administered, either orally or by I. V. infusion, 20 to 30 minutes prior to the treatment with the device 10. The photodynamic therapy treatment can also be administered during or after the polychromatic phototherapy treatment with the device 10.

[0054] Referring to FIG. 9A, housing 11 of device 10 includes a pivotal access panel 20 attached by hinges 22 to stationary panel 24 forming the rear of housing 11. Finger operated latches 26 hold access panel 20 in a closed position until the operator lifts latches 26. Panel 20 is then rotated upward, providing manual and visual access to the light sources and to the triple quartz tube cuvette assembly 66 (FIGS . 10-16) disposed in the interior space of housing 11. [0055] Photodynamic therapy utilizes the administration of any of several photo activated sensitizers or photo-active substances: PAS 1, 2, 3, 4, 5, 6, and 7; psoralen drugs, 8-MOP, porphyrins, curcumin, indocyanine green, chlorins, and liposomal methylene blue. Photodynamic therapy can produce a number of side effects, including increased light sensitivity, “collateral damage” to healthy cells due to a lack of specificity, fatigue, Herkshemier reaction, fever, and/or chills. Photoluminescent therapy comprises four parameters: the amount of blood taken from the patient; time of exposure of the blood to the light; the intensity and the wavelengths of the spectral energy used; and the sensitivity of the photo-active drug, if used in the therapy.

[0056] Referring to FIGS. 10 and 11, the interior of housing 11 of device 10 includes a front light assembly 28 and a rear light assembly 30, with a space forming treatment chamber 32 between the two light assemblies. Front light assembly 28 comprises a front light support panel 34 having a reflective surface 36 facing inward toward treatment chamber 32. Rear light assembly 30 comprises a rear light support panel 38 having a reflective surface 40 facing inward towards treatment chamber 32. Front light support panel 34 includes an angled portion 42, and rear light support panel includes an angled portion 44.

[0057] A first substantially U-shaped LED light housing 46 is attached by a plurality of supports 48 to the interior reflective surface 36 of front light assembly 28. Mounted in the channel formed in first LED light housing 46 is a green LED light assembly strip 50 extending substantially the horizontal length of first LED light housing 46. Due to the angle of angled portion 42 of front light support panel 34, and the lens assembly (FIG. 13 A) described below included in green LED light assembly strip 50, the light emitted by the green LED lights in assembly strip 50 is finely focused and directed downward at an angle towards a specific linear location in chamber 32, for a purpose to be explained. The green light emitted from green LED light assembly strip 50 is optimally 525nm, but could be in the range of 510-540nm.

[0058] Referring to FIG. 13 A, which is a cross section view of first LED light housing 46 and green LED light assembly strip 50 taken along line B-B of Fig. 12, light assembly strip 50 is mounted to the base 52 of housing 46. A plurality of green LED lights 54 are attached in a linear array to, or embedded in, strip 50 (Fig. 12) in the channel 56 formed by light housing 46. A halfround clear glass rod or lens 58 is mounted by adhesive, a grommet or the like over the LED lights 54. A full round clear glass rod or lens 60 is mounted by adhesive or the like to the flat surface 62 of half round glass rod 58. Clips 64 (FIG. 12, 13B) at both ends of light assembly strip 50 hold the green LED light assembly strip 50 and lenses 58, 60 together.

[0059] The green LED light assembly 50 with lenses 58 and 60 described above produces a tight horizontal line of intense visible green light highly focused at the line where the upper tube 65 of triple quartz tube cuvette assembly 66 (FIGS. 10, 11) will be located, as explained in detail below. The green LED light assembly 50 focuses and delivers the highest possible concentration of visible light through one upper tube 65 of the quartz tubes comprising cuvette assembly 66 and into the blood as the blood flows through upper tube 65 of cuvette assembly 66. As will be explained, the same concentration of highly focused light is emitted from each of the other LED light assembly strips directed at the several tubes of triple quartz tube cuvette assembly 66.

[0060] A second U-shaped LED light housing 70 (Figs. 10, 11) is attached to reflective surface 36 of front light support panel 34. A dual wavelength red LED light assembly strip 72 extends linearly substantially along the horizontal length of second LED light housing 70. As seen in FIGS. 10 and 11, light emanating from red LED light assembly strip 72 will be directed in a concentrated and highly focused linear beam to second or middle tube 74 of cuvette assembly 66. Dual red LED light assembly strip 72 comprises alternating diodes of different wavelengths along the strip. For example, positions 1, 3, 5, 7, 9 are either 625nm or 660nm optimally, and positions 2, 4, 6, 8, 10 are the other of these wavelengths. These wavelengths could also be in the range of 610nm-675nm.

[0061] Dual wavelength red LED light assembly strip 72 is structurally the same as described above regarding green LED light assembly strip 50, only the LED lights are red rather than green. The description above regarding the lens structure of FIG. 13 A is equally applicable to dual wavelength red LED light assembly strip 72, except that the LED lights are red, and the light is directed at middle tube 74 of cuvette assembly 66. The above description of a tight line of intense visible light focused on the upper tube 65 of cuvette assembly 66 applies equally here regarding the red LED light focused on middle tube 74 of cuvette assembly 66.

[0062] Referring back to FIGS. 10 and 11, a third U-shaped LED light housing 76 is attached by supports 78 to reflective surface 36 of front light support panel 34. An infrared LED light assembly strip 80 extends linearly substantially along the horizontal length of third LED light housing 76. As seen in FIGS. 10 and 11, light emanating from infrared LED light assembly strip 80 will be directed in a concentrated and highly focused linear beam to third or bottom tube 82 of cuvette assembly 66. Light emanating from infrared LED light assembly strip 80 optimally has a wavelength of 810nm, and could be in the range of 795nm and 825nm.

[0063] Infrared LED light assembly strip 80 is structurally the same as described above regarding green LED light assembly strip 50, only the LED lights are infrared rather than green. The description above regarding the lens structure of FIG. 13 A is equally applicable to infrared LED light assembly strip 80, except that the LED lights are infrared, and the light is directed at bottom tube 82 of cuvette assembly 66. The above description of a tight line of intense visible light focused on the upper tube 65 of cuvette assembly 66 applies equally here regarding the infrared LED light focused on bottom tube 82 of cuvette assembly 66.

[0064] The use of infrared LED therapy, for example, in treating patients with community- acquired pneumonia (CAP) has resulted in significant recovering differences for erythrocytes, hemoglobin, leukocytes, segmented and band neutrophils, lymphocytes and monocytes. The hematology components of CAP patients recover their normal values after including infrared light exposure to the blood. Another advantage of exposing blood to be treated with infrared LED lights is the anti-inflammatory agent.

[0065] Referring to FIGS. 10 and 11, several LED light sources are mounted on reflective surface 40 of rear light assembly 30. A fourth U-shaped LED light housing 84 is attached by supports 85 to reflective surface 40. Mounted in the channel formed by the U-shape of housing 84 is a violet LED light assembly strip 86 extending substantially the horizontal length of fourth LED light housing 84. Due to the angle of angled portion 44 of rear light support panel 38, light emitted by the violet LED lights in assembly strip 86 is directed downward at an angle towards upper tube 65 of cuvette assembly 66. Light emanating from violet LED light assembly strip 86 optimally has a wavelength of 430nm, and could be in a range between 415nm and 445nm.

[0066] Violet LED light assembly strip 86 is structurally the same as described above regarding green LED light assembly strip 50, only the LED lights are violet rather than green. The description above regarding the lens structure of FIG. 13 A is equally applicable to violet LED light assembly strip 86, except for the color of the LED lights. The above description of a tight line of intense visible light focused on the upper tube 65 of cuvette assembly 66 applies equally here regarding light emanating from violet LED light assembly strip 86. Treating the blood in the quartz cuvette with violet LED light provides the advantage of photo activating cur cumin in treating cancer patients. [0067] A fifth U-shaped LED housing 88 is attached directly to reflective surface 40 of rear light support panel 38. Mounted in the channel formed by U-shaped LED housing 88 is an infrared LED light assembly strip 90 extending substantially the horizontal length of fifth LED light housing 88. Light emitted by infrared LED light assembly strip 90 is directed horizontally directly towards middle tube 74 of cuvette assembly 66 as a highly focused linear light beam. The wavelengths of light from infrared LED light assembly strip 90 are the same as described above regarding infrared LED light strip 80.

[0068] Infrared LED light assembly strip 90 is structurally the same as described above regarding green LED light assembly strip 50, only the LED lights are infrared rather than green. The description above regarding the lens structure of EIG. 13 A is equally applicable to infrared LED light assembly strip 90, except for the color of the LED lights. The above description of a tight line of intense visible light focused on the upper tube 65 of cuvette assembly 66 applies equally here regarding light emanating from infrared LED light assembly strip 90 and focused on middle tube 74 of cuvette assembly 66.

[0069] A sixth U-shaped LED housing 92 is attached by a plurality of supports 94 to reflective surface 40. Mounted in the channel formed by the U-shape of housing 92 is a dual wavelength red LED light assembly strip 96 extending substantially the horizontal length of sixth LED light housing 92. Light emitted by the red LED lights in assembly strip 96 is directed towards bottom tube 82 of cuvette assembly 66. Red LED light assembly strip 96 is structurally the same as described above regarding green LED light assembly strip 50, only the LED lights are red. The description above regarding the lens structure of EIG. 13 A is equally applicable to red LED light assembly strip 96, except for the color of the LED lights. The above description of a tight line of intense visible light focused on the upper tube 65 of cuvette assembly 66 applies equally here regarding light emanating from red LED light assembly strip 96 and focused on bottom tube 82 of cuvette assembly 66. Red LED light assembly strip 96 comprises alternating diodes of different wavelengths along the strip. For example, positions 1, 3, 5, 7, 9 are either 625nm or 660nm, and positions 2, 4, 6, 8, 10 are the other of the wavelengths.

[0070] Referring to FIG. 12, a rigid bracket 98 extends laterally from front light support panel 34. The base 100 of a high output UVC light source 102 in the range of 253.7nm is firmly mounted to bracket 98, with a power connector 104 extending through aperture 106 in bracket 98. UVC light source 102 comprises a U-shaped fluorescent tube 108 as is known in the art. A space 110 is formed between each pass of U-shaped tube 108 for purposes to be described. [0071] Referring to FIG. 13B and FIG. 12, clip 64 supporting red LED light assembly strip 72 in second LED light housing 70 includes a U-shaped bracket 112 that extends adjacent the outer surface of high power UVC tube 108, securing tube 108 vertically. Wire 114 extends between the open ends of bracket 112 to secure U-shaped tube 108 horizontally. As seen in FIGS. 11 and 12, focused light emanating from red LED light assembly strip 72 will travel in space 110 unimpeded before being focused on middle tube 74 of cuvette assembly 66. In similar fashion, infrared LED light assembly strip 80 is located below U-shaped UVC tube 108, allowing focused light to pass unimpeded from infrared LED light assembly strip 80 to bottom tube 82 of cuvette assembly 66.

[0072] Referring to FIG. 13, a rigid bracket 116 extends laterally from rear light support panel 38. The base 118 of a high power dual wavelength UVA light source 120 emitting UVA light in wavelengths of 340nm and 365nm is firmly mounted to bracket 116, with a power connector 122 extending through an aperture (not shown) in bracket 116. UVA light source 120 comprises a U-shaped fluorescent tube 124 as is known in the art. A space 126 is formed between each pass of U-shaped UVA tube 124 for purposes to be described.

[0073] Referring to FIG. 13B and FIG. 13, clip 64 holding infrared LED light assembly strip 90 in fifth LED light housing 88 includes a second U-shaped bracket 112 that extends adjacent the outer surfaces of UVA tube 120, securing tube 120 vertically. Second wire 114 extends between the open ends of second bracket 112 to secure U-shaped tube 124 horizontally. As seen in FIGS. 11 and 13, focused light emanating from infrared LED light assembly strip 90 will travel unimpeded in space 126 before being focused on middle tube 74 of cuvette assembly 66. In similar fashion, red LED light assembly strip 96 is located below U-shaped UVA tube 120, allowing focused light to pass unimpeded from red LED light assembly strip 96 to bottom tube 82 of cuvette assembly 66.

[0074] Referring to FIG. 14, the disposable triple quartz tube cuvette assembly 66 of the presently disclosed device is shown. Cuvette assembly 66 comprises three hollow quartz tubes 65, 74, 82 mounted parallel to each other. Flexible loop 130 connects tube 65 to tube 74 and flexible tube 131 connects tube 74 to tube 82, providing a single path for blood to flow in either direction through cuvette assembly 66. A pair of cuvette supports 132 hold opposite ends of tubes 65, 74 and 82 in their proper vertical location, as will be explained. Inlet tubing lead 134 is attached to tube 82 and is adapted to communicate at end 135 with a standard infusion set for withdrawing blood from a patient. A port 136 is adapted to connect inlet tubing lead 134 with a syringe if needed to treat clotting or any other anomalies at the venipuncture. Inlet tubing lead 134 is connected to bottom tube 82 of cuvette tube 128 on the patient side. Outlet tubing lead 138 is connected to upper tube 65 of cuvette assembly 66, and to a reservoir 160 at end 140 of outlet tubing lead 138.

[0075] Also illustrated in FIGS. 14 and 15 is reflective tray 142 attached to the bottom surface 143 (FIG. 15) of housing 11. Tray 142 has a reflective top surface 144 that assists in reflecting light from the various UV and LED light sources to tubes 65, 74 and 82 of cuvette assembly 66 . Opposed brackets 146, 148 extend upward from reflective tray 142, and slots 150, 152 are adapted to receive the portions of tubes 65, 74 and 82 extending outwardly beyond cuvette supports 132. Open top slots 150, 152 support cuvette assembly 66 in a correct vertical position when cuvette assembly 66 is placed in treatment chamber 32 between the front and rear light sources. When tube 128 is properly located in slots 150, 152, disposable cuvette assembly 66 can be manually inserted in and removed from treatment chamber 32 in housing 11. When cuvette assembly 66 is fully inserted into slots 150,152, the bottom of each cuvette support 132 rests on reflective surface 144 of tray 142 to properly vertically position tubes 65, 74 and 82, in relation to the various light sources described above.

[0076] FIGS. 16 and 17 illustrate a topical wrist pad 18 accessory comprising a densely populated plurality of deep red/photored LED lights 156 on surface 154 to promote a photodynamic therapy treatment when a wrist pad 18 is applied to a patient's wrist using strap 157. FIG. 16 illustrates two wrist pads 18. Each wrist pad 18 is powered by electrically connecting the wrist pad to a USB port 16 (FIG. 9A) via a power cord 160 (FIG. 16). When activated, the wavelengths of the red LED lights 156 stimulate an immune system response in the patient. This is significant for blood flow, is deeply penetrating, and is easy to access via the radial and ulnar arteries (FIG. 7). The intensity of the deep red/photored LED lights 156 is controlled by one of the intensity touch screen slider control switchs 14 on display panel 9 (FIGS. 9A,B,C). [0077] Referring to FIG. 17, the wavelengths of red LED lights LI, L3, L5, L7 and L9 are all one of either approximately 625 nm or approximately 650nm. The wavelengths of red LED lights L2, L4, L6, L8 and LIO would be the other of those two wavelengths.

[0078] The high power dual wavelength UVA light source 120 (FIG. 13) includes a custom made U-shaped high output bulb 124 that emits the primary wavelength that stimulates NADH and NAD+ in blood. The high output UVC light source 102 (FIG. 12) includes a high output bulb 108 in the primary germicidal UVC band, which stimulates NAD and general germicidal and virus inactivation in blood. The device 10 in the illustrated embodiment utilizes very specialized custom made bulbs, constructing photonic architecture that supports and up regulates NAD+ and NADH, which are integral for the resultant production of ATP. The device 10 can also provide up regulation of the chylomicron albumen component of the blood.

[0079] Dual wavelength red LED lights in assemblies 72 and 96 (FIG. 10), which in this exemplary implementation emit light in wavelengths of approximately 625nm and 660nm, support the outer valence of the blood's primary enzymes, such as super oxide dismutase (S.O.D.), catalese, and the other elements of our primary nucleotides, and promote and increase mitochondrial energy. Red light wavelengths are also known to stimulate immune response.

[0080] Infrared lights 80, 90, in assemblies 76, 88 (FIG. 11) significantly increase mitochondrial energy, cleanse blood infections and improve blood oxygenation. Violet lights in assembly 86 photoactivate curcumin, which is sometimes used to improve immune function and attack cancers.

[0081] Infrared LED light assembly 90, which in this exemplary implementation emit light in wavelengths of approximately 810nm, support production and release of NO. Recent findings indicate that low intensity light (810nm ± 14nm) stimulates Cco/NO activity under both hypoxic and, to a lesser extent, normoxic conditions, providing an alternative explanation for the increase in NO bioavailability observed during photomodulation. These new findings indicate that low level light stimulates new NO synthesis from Cco/NO and does not merely release NO from preexisting tissue stores. Because the NO produced by Cco/NO can be used both inside cells, where it functions in hypoxic signaling, and outside of cells, where it may function in vasodilation and other signaling pathways, it is likely to have a multitude of effects. Additionally, the use of the amber light source in combination with St. John’s Wort helps promote wellbeing and reversing depression, which is very important in the treatment of cancers and chronic conditions. The use of St. John’s Wort and, if desired, curcumin for three days prior to treatment with the device 10 is recommended to enhance anti-depression results. The resulting elevated serotonin level helps all treatment therapies to be better tolerated as it improves mood.

[0082] It has been established that low level laser therapy, when used on human blood in vitro, affects the rheology of erythrocytes and leucocytes. It has also been observed that low level laser therapy changes the erytherocytatory, leucocytatory, BSR, and aggregability indices of blood. Therefore, green LED light assembly 50 (FIG. 11), which in this exemplary implementation emits light in a wavelength of approximately 525nm, can affect the physical as well as chemical properties of blood cells, which is not only helpful in the preservation of blood but also in revitalizing the physically and chemically stressed erytherocytatory membranes. It has been determined that the light decreases the viscosity of blood, thus increasing the electrophoretic mobility of erythrocytes. The green LED light 50 affects the rheology of erythrocytes and leucocytes, and chemical properties of blood cells revitalizing the physically and chemically stressed erythrocytatory membranes. Blue-green light is also known to balance the redox processes within the cells.

[0083] The cuvette assembly 66 (FIG. 14) comprises three connected hollow quartz tubes, each tube comprising an approximate twelve inch length portion in a parallel arrangement. The sterile, disposable cuvette assembly 66 has 300% of the surface area as any other cuvette assembly available today, which lengthens the time blood components are exposed to the photonic energy by 300% and facilitates three times the energy absorption and triple the exposure “travel” time. The treatment chamber 32 (FIG. 10) is accessed by lifting up access panel 20 of the device 10 using dual pressure latches 26 (FIG. 9A), to open and access the treatment chamber 32 for insertion and removal of the cuvette assembly 66. The cuvette assembly 66 is mounted on the brackets 146, 148 located in the treatment chamber 32. Only the cuvette assembly, and the blood that travels through it, will be exposed to the LED lights. The cuvette assembly 66 is inserted into the treatment chamber 32 with the flexible tube 138 exiting the device 10 through the slots 150, 152 provided in brackets 146, 148, with the input tubing lead 135 at the bottom of the cuvette assembly 66 on the patient side (Fig. 14). This way the blood flow will start at the bottom of the cuvette assembly 66. As the blood enters the triple tube quartz cuvette assembly 66, the blood's initial exposure is to a short band red wavelength 96 which significantly upgrades the primary protective enzymes, such as S.O.D. and catalase that maintain the red blood cells’ ability to be exposed to the additional light wavelengths of the device 10 with no danger of generating met heme. The entering blood is also exposed to infrared LED light source 80, which up regulates ATP production.

[0084] Blood is drawn directly from the patient through the cuvette assembly 66 and connected tubing into a reservoir 160, (FIG. 14). Photo luminescence exposure occurs in both directions, when the blood is drawn from, and returned to, the patient. The polychromatic phototherapy device 10 enables the medical professional to increase contact time and/or exposure of the blood 300% - 600% longer than existing devices.

[0085] The device 10 cooling mechanism includes a plurality of high flow cooling fans suitably placed in housing 11 to maintain proper operating temperature and to keep internal electronics within optimal operating temperatures. An adequate number of cooling fans are disposed on the inside surface of a rear panel (not shown) of the device 10. An additional assembly of cooling fans are disposed on the inside surface of the front panel of the device 10. The fan arrangement is optimally designed to pull air into the treatment chamber 32 through apertures in the front of the device through louvers in the bottom of housing 11. Air is extracted from housing 11 by means of a plurality of high CFM (cubic feet per minute) fans in the rear panel to provide cooling of the high intensity light sources and to extract heated air. The U- shaped bulb UV lamps 108, 124 are housed in the device 10 in such a manner as to stabilize and maintain proper operating temperature and eliminate any foreign matter contact. A thermal infused type ETL, CSA, and CE line filter (not shown) is employed to significantly reduce system electromagnetic emissions. A high output power supply is provided, as is known in the art.

[0086] Several items are required for treatment with the illustrated embodiment of the polychromatic phototherapy device 10, including, but not limited to, one 10 cc syringe, alcohol preps, cotton balls or wipes, bandages, two clamps, 50 cc of normal saline or greater, one vented UV tubing set (only used with a vacuum bottle or bag), one sterile cuvette cartridge 66, one cc of 5,000 units + or - of heparin or equivalent sodium citrate for blood thinning to prevent clotting during treatment, one tourniquet, one 250 cc or 500 cc sterile evacuated container or saline bag, 60 cc syringes, 2x2 gauze pads, typical 19 - 21 gauge butterfly needle or 20 - 22 gauge angio- catheter, and disposable gloves. [0087] The photo luminescence treatment procedure can be administered using the device 10 in several ways. In this implementation, the device 10 can be used to administer the photoluminescence treatment using the push-pull syringe technique, the saline bag infusion technique, the in-line multipass Zotsmann or Hermann hyperbaric ozone technique, pheresis systems, and the veterinary syringe technique.

[0088] As a general rule of thumb, patients must be well hydrated prior to treatment to promote ease of blood flow. The patient may be further hydrated intravenously prior to treatment. Additionally, the operator must ensure that the patient has eaten prior to treatment and that the patient’s blood sugar is in normal range as possible for the patient. Before beginning treatment with any of these procedures, the operator must weigh the patient and calculate the amount of blood to withdraw using the following formula:

Weight (in pounds) x 1.5 = number of cc’s of blood to draw.

[0089] If the amount of blood to be treated is less than 250 cc, a mark is placed on the bottle or bag where the appropriate amount of blood will have been withdrawn. The area where the procedure is conducted should be hygienically clean and the operator should have all needed supplies at hand. A reclining chair may be provided to allow the patient to recline in the event of lightheadedness, or similar symptoms, while the procedure is progressing.

[0090] It is also recommended that the patient take St. John’s Wort or curcumin for three days prior to treatment as these molecules promote the release of nitric oxide and also affect a general state of wellbeing as a resultant reaction to the absorption of wavelengths emitted by the polychromatic phototherapy device 10.

[0091] Certain techniques described below are easier to perform if gravity is used to promote aspiration and reinfusion. Therefore, for aspiration the device 10 should be positioned below the venipuncture and the reservoir blood collection bag or bottle 160 (FIG. 14) below that point. Reversing the positions would aid in reinfusion.

[0092] FIG. 18 is a flow diagram showing a process 162 for treating blood using the polychromatic phototherapy device 10 in accordance with an implementation of this disclosure. Process 162 uses a push-pull syringe technique that begins by ascertaining the correct amount of blood to be aspirated 164 by the pre-approved doctor’s protocol using the Knott Technique, 1 to 1.5 cc to 1 pound of body weight as indicated above. The cuvette assembly 66 is then placed in the treatment chamber 32 in the device 10, 166, taking care to be certain that the cuvette assembly 66 is resting on the reflective tray 142 (FIG. 10) of the treatment chamber 32. [0093] Connect a 60cc syringe to the cuvette assembly and prime the cuvette with about 30cc of heparinized salinel68. Prepare the venous site by cleansing the area with an alcohol prep. [0094] Once an appropriate site has been located, proceed with cannulation using either a 19 - 21 gauge butterfly or a 20 gauge catheter 170. As light has significant biological benefits, you may turn on all LED light sources, red, green, infrared and violet. Withdraw the appropriate amount of blood, maximum of 30cc, and then reinfuse the blood into the patient 174. Attach a 60 cc syringe to the female Leur lock end of the cuvette cartridge 66. Re-aspirate until the appropriate amount of blood has been treated, then push balance of blood back into the patient. Optionally, place topical wrist pads 18 (FIGS. 16, 17) on the patient to administer photodynamic therapy treatment, in this illustrated embodiment, using liposomal methylene blue.

[0095] There are adjustments for the intensity of accessory devices on the device 10, such as wrist pads 18. Adjust the intensity using the touch screen slidable intensity switches 14 on the display panel 9 of device 10 (FIG. 9A). Full intensity is recommended unless this is too uncomfortable for the patient. Turn on all light sources by using switches 12. It is sometimes necessary to flush the venipuncture area with heparin solution to reestablish aspiration and reinfusion if necessary before starting the flow of blood from the patient and when returning blood to the patient. The cuvette assembly 66 has an additional lead with port 134 (FIG. 14) to make this more convenient. If the pressure is too great in either direction, do not push harder as a rupture in the cuvette cartridge 66 may occur. Stop and turn off all light sources (FIG. 9B). Determine the cause of the clotting, which is usually at the venipuncture. Clear the obstruction, reactivate all light sources and continue. Repeat until the appropriate quantity of blood has been treated and then push the balance of blood back into the patient 176. Once the treatment has been completed, dispose of all materials appropriately.

[0096] FIG. 19 is a flow diagram showing a process 182 for treating blood using the polychromatic phototherapy device 10 in accordance with an implementation of this disclosure. Process 182 uses a saline bag infusion technique that begins by assembling an I.V. (infusion set) tubing set and connecting the infusion set to cuvette assembly 66 using a sterile technique and creating a closed system. Do not use a filter of any kind as it may restrict blood flow. Care must be taken not to touch the surface of the cuvette assembly 66 tubes, as fingerprints will impede penetration of the UV light sources. If body oils are inadvertently left on the quartz tubes of the cuvette assembly 66 surface, wipe off with plain alcohol. The cuvette assembly 66 is placed in the treatment chamber 32 in the device 10, 186, taking care to be certain that the cuvette assembly is resting on the reflective tray 142 of the treatment chamber 32. Handle the cuvette assembly 66 by placing the cuvette assembly 66 into the treatment chamber 32 of the device 10, or by the standoffs or flexible tubing of the cuvette assembly 66. Follow procedures for attaching and adjusting optional topical pads 190, if used, as described above. Select an appropriate size bag of normal saline, either 250 cc or 500 cc, and hang on an I.V. pole 188. Infuse the appropriate amount of heparin, for example 2500 - 5000 units, and prime the cuvette assembly 66 with this solution 200. Clamp off the infusion set 201, and establish a venipuncture using either a 19 gauge butterfly or a 20 gauge angio catheter 202. Open the infusion set clamp and drip the majority of the saline/heparin solution into the patient 204. For example, if using a 250 cc saline bag the operator may want to infuse 150 cc of the saline, or in the case of a 500 cc saline bag the operator may want to infuse 350 cc of saline, into the patient. Now the patient has been heparinized and has received some hydration. Lower the saline/collection bag below the site of the venipuncture and begin aspiration 206. Turn on all desired light sources 208 (FIG. 9B). Gravity will assist in the collection of the desired amount of blood. When the desired quantity of blood has been collected, turn off all light sources 210. Raise the bag and reinfuse at a rapid drip rate 210, at least 10 cc per minute. Ozone (FIG. 8) may be added for additional oxidative enhancement if desired. Ozone may be infused into the bag with the collected blood with syringes up to the amount of the blood in the bag, 1 to 1. When all blood has been returned to the patient, dispose of all materials as appropriate.

[0097] FIG. 20 is a flow diagram showing a process 212 for treating blood using the polychromatic phototherapy device 10 in accordance with an implementation of this disclosure. Process 212 uses an in-line multipass hyperbaric ozone technique that begins with following all preparation procedures as indicated previously and setting up the hyperbaric ozone machine (not shown) or pheresis machine (not shown) 214, following their respective setup procedures as described by their manufacturers. The cuvette assembly 66 is placed in the treatment chamber 32 in the device 10, 216, taking care to be certain that the cuvette assembly 66 is resting on the reflective tray 142 of the treatment chamber 32. Connect the cuvette assembly 66, which has been inserted into the treatment chamber 32 of the device 10, in line with the leads for each of the appropriate device 218. The device 10 is connected in line with the appropriate device, which pulls and pushes the blood through the cuvette assembly 66 into a container and then reinfuse back through the cuvette assembly 66 into the body from the same cannula as the blood had been withdrawn 220. Conduct the treatment procedure as normal with either of them 222, making sure that pressure does not exceed 0.7 atm (atmospheres) as indicated on either device. The pheresis device will withdraw blood from one cannula, pass the blood through the device, and reinfuse the blood into a cannula of the opposite arm.

[0098] FIG. 21 is a flow diagram showing a process 224 for treating blood using the polychromatic phototherapy device 10 in accordance with an implementation of this disclosure. Process 224 uses a first embodiment of a veterinary syringe technique. As our four legged friends are generally much smaller in body weight than we are, only about 1.5 cc of blood per pound of body weight should be treated.

[0099] Process 224 uses a push-pull syringe technique that begins by ascertaining the correct amount of blood to be aspirated by the preapproved doctor's protocol using the Knott Technique, 1 to 1.5 cc to 1 pound of body weight as indicated above. The cuvette assembly 66 is then placed in the treatment chamber 32 in the device 10, 226, taking care to be certain that the cuvette assembly 66 is resting on the reflective tray 142 (FIG. 10) of the treatment chamber 32.

[00100] Connect a 66cc syringe to the cuvette assembly and prime the cuvette with about 30cc of heparinized saline 227. Prepare the venous site by cleansing the area with an alcohol prep.

[00101] Once an appropriate site has been located, proceed with cannulation using either a 19 - 21 gauge butterfly or a 20 gauge catheter 170, 227. As light has significant biological benefits, you may activate all light sources 229. Withdraw the appropriate amount of blood, maximum of 30cc, and then reinfuse the blood into the patient 230. Attach a 60cc syringe to the female Leur lock end of the cuvette cartridge 66. Re-aspirate until the appropriate amount of blood has been treated, then push balance of blood back into patient. 232. Optionally, place topical wrist pads 18 (FIGS. 16, 17) on the patient to administer photodynamic therapy treatment in this illustrated embodiment, using liposomal methylene blue.

[00102] Any of these above-described treatment techniques with the polychromatic phototherapy device 10 can be used with intravenous infusion of methylene blue or the administration of liposomal methylene blue treatment with photodynamic therapy, or other suitable photodynamic substances. [00103] The procedure for administration of liposomal methylene blue includes the following steps: withdraw 0.5 to 1 cc of solution and place in the buccal region of the mouth. Hold for one minute to facilitate maximum capillary absorption, then take a sip of fluid and swallow. Do this approximately 20 minutes prior to treatment with the device 10 to enable the methylene blue to be absorbed internally.

[00104] As used in this application, the term "or" is intended to mean an inclusive "or" rather than an exclusive "or". That is, unless specified otherwise, or clear from context, "X includes A or B" is intended to mean any of the natural inclusive permutations. That is, if X includes A; X includes B; or X includes both A and B, then "X includes A or B" is satisfied under any of the foregoing instances. In addition, “X includes at least one of A and B” is intended to mean any of the natural inclusive permutations. That is, if X includes A; X includes B; or X includes both A and B, then “X includes at least one of A and B” is satisfied under any of the foregoing instances. The articles "a" and "an" as used in this application and the appended claims should generally be construed to mean "one or more" unless specified otherwise or clear from context to be directed to a singular form. Moreover, use of the term "an implementation" or "one implementation" throughout is not intended to mean the same embodiment, aspect or implementation unless described as such.

[00105] While the present disclosure has been described in connection with certain embodiments and measurements, it is to be understood that the present disclosure is not to be limited to the disclosed embodiments and measurements but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the scope of the appended claims, which scope is to be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures as is permitted under the law.

Claims

I claim:

1. A polychromatic phototherapy device for blood treatment, comprising: a casing; a cuvette assembly adapted to transport blood through a hollow continuous tube comprising the cuvette, the hollow tube having an entrance and an exit, the cuvette assembly removably installed in the casing; the cuvette assembly further comprising a plurality of clear quartz tubes mounted in a cuvette assembly support structure, each clear quartz tube connected to at least one other clear quartz tube to form a single flow path through the plurality of quartz tubes; a first clear quartz tube located at the bottom of the cuvette assembly, a second clear quartz tube located above the first clear quartz tube, and a third clear quartz tube located above the second clear quartz tube; a plurality of light sources in the casing, the light sources positioned adjacent the cuvette assembly when the cuvette assembly is installed in the casing; the plurality of light sources including a source of UVA light, a source of UVC light, and a plurality of LED light source, the plurality of light sources arrayed in the casing and configured to focus concentrated light beams on the blood as the blood is conveyed through the hollow continuous tube of the cuvette assembly; the plurality of LED light sources including light emitted from at least one dual wavelength red LED light source and at least one infrared LED light source focused on the first clear quartz tube, light emitted from at least one infrared LED light source and a dual wavelength red LED light source focused on the second clear quartz tube, light emitted from at least one green LED light source focused on the third clear quartz tube, and light emitted from at least one violet LED light source also focused on the third clear quartz tube.

2. A polychromatic phototherapy device for blood treatment, comprising: a casing; a cuvette assembly configured to transport blood through a hollow continuous tube comprising the cuvette, the hollow tube having an entrance and an exit, the cuvette assembly removably installed in the casing; the cuvette assembly further comprising a plurality of clear quartz tubes mounted in a cuvette assembly support structure, each clear quartz tube connected to at least one other clear quartz tube to form a single blood flow path through the plurality of quartz tubes; a plurality of light sources in the casing, the light sources positioned adjacent the cuvette assembly when the cuvette assembly is installed in the casing; the plurality of light sources including a source of UVA light, a source of UVC light, and a plurality of LED light sources, the plurality of light sources arrayed in the casing and configured to focus concentrated light beams on the blood as the blood is conveyed through the hollow continuous tube of the cuvette assembly; the plurality of LED light sources including light emitted from at least one dual wavelength red LED light source and from at least one infrared light source focused on a first and second clear quartz tube, and light emitted from at least one green LED light source and at least one violet LED light source focused on a third clear quartz tube.

3. The polychromatic phototherapy device of claim 2, wherein: the UVA light source is a high power dual wavelength UVA light source emitting light in the wavelengths of 340nm and 365nm .

4. The polychromatic phototherapy device of claim 2, wherein: the UVC light source is a high output UVC light source emitting light in the wavelength of 253.7nm .

5. The polychromatic phototherapy device of claim 2, wherein: the light emitted from the dual wavelength red LED light source is in the wavelength range of 610nm to 675nm.

6. The polychromatic phototherapy device of claim 5, wherein: the light emitted from the dual wavelength red LED light source comprises wavelengths of 625nm and 660nm.

7. The polychromatic phototherapy device of claim 2, wherein: the light emitted from the infrared LED light source is in the wavelength range of 795nm to 825nm .

8. The polychromatic phototherapy device of claim 7, wherein: the light emitted from the infrared LED light source comprises a wavelength of 810nm.

9. The polychromatic phototherapy device of claim 2, wherein: the light emitted from the green LED light source is in the wavelength range of 510nm to 540nm .

10. The polychromatic phototherapy device of claim 9, wherein the light emitted from the green LED light source comprises a wavelength of 525nm.

11. The polychromatic phototherapy device of claim 2, wherein: the light emitted from the violet LED light source is in the wavelength range of 430nm to 465nm .

12. The polychromatic phototherapy device of claim 11, wherein: the light emitted from the violet LED light source comprises a wavelength of 430nm.

13. The polychromatic phototherapy device of claim 2 wherein: the entrance to the hollow continuous tube is connected to one end of a flexible input tubing lead, a second end of the flexible input tubing lead configured to be connected to an infusion set for withdrawing blood from a patient.

14. The polychromatic phototherapy device of claim 2, wherein: the exit of the hollow continuous tube is connected to a fluid reservoir by a flexible exit tubing lead , the reservoir adapted to collect fluid subsequent to the fluid flowing through the cuvette assembly.

15. The polychromatic phototherapy device of claim 2, wherein: one end of a flexible input tubing lead is connected to one end of the first clear quartz tube; one end of a flexible exit tubing lead is connected to one end of the third clear quartz tube; a second end of the first clear quartz tube is fluidly connected to a first end of the second clear quartz tube; and a second end of the second quartz tube is fluidly connected to a first end of the third clear quartz tube.

16. The polychromatic phototherapy device of claim 2, wherein: each of said UVA and UVC light sources comprises a U-shaped fluorescent light bulb and a space between each portion of the U-shaped bulbs, each space positioned adjacent the second clear quartz tube; light emanating from one of the infrared LED light sources and light emanating from one of the dual wavelength red LED light sources passing through one of said spaces when the infrared and red LED light sources are focused on the second clear quartz tube.

17. The polychromatic phototherapy device of claim 2, wherein: light emitted from one red LED light source and light from one infrared LED light source are focused on the second clear quartz tube of the cuvette assembly.

18. The polychromatic phototherapy device of claim 2, wherein: light emitted from one red LED light source and light from one infrared LED light source are focused on the first clear quartz tube of the cuvette assembly.

19. The polychromatic phototherapy device of claim 2, wherein: a plurality of brackets are attached to LED light housings, the plurality of brackets removably supporting the UVA and UVC light sources adjacent the cuvette assembly.

20. A polychromatic phototherapy device to treat blood flowing through a user's wrist, comprising: a pad configured to be removably attached to the user's wrist; a plurality of red/photored LED lights disposed on one surface of the pad, a first portion of the plurality of red/photored LED lights emitting light at a wavelength of 625nm, and a second portion of the plurality of red/photored LED lights emitting light at a wavelength of 650nm; and a source of electric power connected to the plurality of red/photored LED lights.

21. The polychromatic phototherapy device of claim 1, further comprising: at least one pulse generator electrically connected to the LED light sources; and at least one manually operated switch on the casing, the at least one manually operated switch operable when activated varying the pulse rate of an associated LED light source.

22. The polychromatic phototherapy device of claim 21, wherein: the pulse rate is variable between 0.1 cycles per second to 20,000 cycles per second.

23. A polychromatic phototherapy device for blood treatment, comprising: a casing; a cuvette assembly adapted to transport blood through a hollow continuous tube comprising the cuvette, the hollow tube having an entrance and an exit, the cuvette assembly removably installed in the casing; the cuvette assembly further comprising at least one tube mounted in a cuvette assembly support structure, each at least one tube forming a single flow path through the tube; a plurality of LED light sources in the casing, the light sources positioned adjacent the cuvette assembly when the cuvette assembly is installed in the casing; the plurality of LED light sources arrayed in the casing and adapted to focus concentrated light beams on the blood as the blood is conveyed through the hollow tube of the cuvette assembly; at least one pulse generator electrically connected to the LED light sources; at least one manually operated switch on the casing, the at least one manually operated switch operable when activated to vary the pulse rate of an associated LED light source.

24. A method for the polychromatic phototherapy treatment of blood, comprising: a. preparing a patient for the withdrawal of blood from the patient and for the reinfusion of blood back into the patient; b. determining a correct amount of blood to be treated; c. initiating the circulatory flow of the determined amount of blood from the patient and back into the patient. d. treating the blood by exposing the blood flowing in a quartz cuvette assembly to at least one dual wavelength UVA light source, at least one UVC light source, at least one dual wavelength red LED light source, at least one infrared LED light source, at least one green LED light source, and at least one violet LED light source; e. reinfusing the treated blood into the patient.

25. The method of claim 24, further comprising: infusing heparin into a container to create a saline/heparin solution and priming the quartz cuvette assembly with the solution; placing a cannula into a vein of the patient; dripping a portion of the saline/heparin solution into the patient; attaching a syringe to an input end of the triple quartz tube cuvette assembly; withdrawing, using the syringe, blood from the patient; treating the blood by passing the blood through the quartz cuvette assembly while the blood passing through the cuvette assembly is exposed to the at least one dual wavelength UVA light source and the at least one UVC light source, and to the dual wavelengths of the at least one red LED light, the at least one infrared LED light, the at least one green LED light source, and the at least one violet LED light source are focused upon selected portions of the quartz cuvette assembly.

26. The method of claim 24, further comprising: infusing heparin into a container to create a saline/heparin solution and priming a quartz cuvette assembly with the solution; placing a cannula into a vein of the patient, dripping a portion of the saline/heparin solution into the patient; lowering the container of saline/heparin solution below the site of the cannula; aspirating blood from the patient into the quartz cuvette assembly; treating the blood by passing the blood through the quartz cuvette assembly while the blood passing through the quartz cuvette assembly is exposed to the at least one dual wavelength UVA light source and the at least one UVC light source, and to the dual wavelengths of the at least one red LED light source, the at least one infrared LED light source, the at least one green LED light source, and the at least one violet LED light source are focused upon selected portions of the quartz cuvette assembly; and reinfusing the blood into the patient at a preselected drip rate of at least lOcc per minute.

27. The method of claim 24, further comprising: providing a multipass hyperbaric ozone technique machine; connecting the leads of a quartz cuvette assembly with the leads of the one multipass hyperbaric ozone technique machine; placing a cannula into a vein of the patient, aspirating, using the multipass hyperbaric ozone technique machine, blood from the patient into the quartz cuvette assembly; treating the blood by passing the blood through the quartz cuvette assembly while the blood passing through the cuvette assembly is exposed to the at least one dual wavelength UVA light source and the at least one UVC light source, and to the dual wavelengths of the at least one red LED light source, the at least one infrared LED light source, the at least one green LED light source and the at least one violet LED light source are focused upon selected portions of the quartz cuvette assembly.

28. The method of claim 26, further comprising: filling a syringe with a predetermined amount of saline and blood thinner; and withdrawing the treated blood into the syringe prior to reinfusing the treated blood into the patient.

29. The method of claim 26, further including the steps of: collecting a first pass of blood after passing the blood adjacent to the light sources ; and conveying the blood in a second pass adjacent the light sources prior to reinfusing the blood into the patient.